Table 3 Mortality studies in hyperthyroidism: treatment groups vs disease-free/population controls
From: Should radioiodine now be first line treatment for Graves’ disease?
Author (ref) | Year | Country | Setting | No of patients | Total/CV mortality RR (95%CI) | Cancer mortality RR (95%CI) |
|---|---|---|---|---|---|---|
Radioactive Iodine vs disease-free/population controls | ||||||
Goldman [12] (a) | 1988 | USA | Hospital | 1762 | Increased; SMR 1.3 (1.2, 1.4) | No difference; SMR 0.9 (0.7, 1.1) |
Goldman [12] (b) | 1988 | USA | Hospital | 607 | Increased; SMR 1.2 (1.1, 1.4) | No difference; SMR 1.0 (0.7, 1.3) |
1992, 1993 | Sweden | Hospital | 10,552 | Increased; SMR 1.5 (1.4, 1.5) | Increased; SMR 1.1 (1.0, 1.2) | |
1998, 1999 | UK | Register | 7209, 7417 (c) | Increased; SMR 1.1 (1.1, 1.2) | Decreased; SMR 0.9 (0.8, 0.9) | |
Ron [17] | 1998 | USA/UK | CTTFUS | 35,593 | NA | No difference; SMR 1.0 (0.9, 1.0) |
Metso [18] | 2007 | Finland | Hospital | 2793 | Increased; SMR 1.1 (1.0, 1.2) | Increased; RR 1.3 (1.1, 1.6) |
Kitahara [11] | 2019 | USA/UK | CTTFUS | 18,805 | NA | Increased; RR 1.1 (1.0, 1.1) |
Antithyroid Drugs vs disease-free/population controls | ||||||
Ron [17] | 1998 | USA/UK | CTTFUS | 35,593 | NA | Increased; SMR 1.3 (1.1, 1.6) |
Boelaert [7] | 2013 | UK | Hospital | 1036 (d) | Increased; SMR 1.3 (1.1, 1.6) (d) | No difference; SMR 1.0 (0.7, 1.6) |
Okosieme [8] | 2019 | UK | Registry | 3587 | Increased; RR 1.2 (1.0, 1.5) | NA |
Thyroidectomy vs disease-free/population controls | ||||||
Ryodi [19] | 2013 | Finland | Registry | 4334 | No difference; RR 0.91, (0.8, 1.1) (e) | NA |